Psilocybin-focused mental health care company COMPASS Pathways plc (NASDAQ: CMPS) announced Monday it had achieved positive results from its exploratory study of COMP360 psilocybin therapy in conjunction with SSRI use. SSRI, or selective serotonin reuptake inhibitors, are the most commonly prescribed antidepressants.
The study revealed that SSRI medications combined with psilocybin treatment do not interfere with psilocybin’s therapeutic effect.
Study Highlights And Results
- This open-label study included 19 patients from clinical sites in Ireland and the United States. The majority of patients were female (68.4%) and the average age was 42 years. The primary endpoint was the change in baseline MADRS1 total score at 3 weeks in patients having 25mg COMP360 psilocybin therapy given in augmentation with their existing SSRI antidepressant regimen.
- COMP360 psilocybin therapy using a 25mg dose showed overall signs of improvement in most other measures including improvement in …